article thumbnail

2025 Merkin Prize in Biomedical Technology awarded to pioneers of CAR T-cell therapy

Broad Institute

A similar CAR from another company, Kite Pharmaceuticals (now a Gilead company), was approved by the FDA in 2017 as the second commercial CAR T-cell therapy. After their clinical results, their technology was licensed to Juno Therapeutics (later acquired by Bristol Myers Squibb.)

article thumbnail

FDA takes major step to ease access to CAR-T therapy

BioPharma Drive: Drug Pricing

Dive Insight: Since the FDA’s approval of Novartis’ Kymriah for leukemia in 2017, six more CAR-T therapies have reached market. These medicines are made from a patient’s own immune cells, extracted from the body and engineered in a lab to hunt down specific proteins found on the surface of malignant clones.

Insiders

Sign Up for our Newsletter

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

article thumbnail

H20 Summit to Shape G20 Health Agenda and Financing

The Pharma Data

Since the inception of the G20 Health Ministers’ Meeting in 2017, the H20 Summit has grown into a central convening space that links public health advocacy with high-level policy and investment strategy. Hanan Al Kuwari, Advisor to the Prime Minister for Public Health Affairs, Qatar H.E.

article thumbnail

The Uncertain Origins of Aspirin

Codon

A study using 2017 interview data suggested that 23.4 But it does matter whether people believe, for instance, that vaccination is the best way to prevent measles. percent of adults 40 years or older in the U.S. estimated to be about 29 million people) took daily aspirin to prevent cardiovascular disease.

article thumbnail

Michelson Prizes, Next-Generation Grants ePanel Features Rising Stars in Immunology & Vaccine Innovation

keypoint

These Next-Generation Grants aim to encourage and support early-career researchers who are applying disruptive concepts and inventive processes to advance human immunology, vaccine discovery, and immunotherapy research.

article thumbnail

CDC: Vaccination Coverage Generally High by Age 24 Months

The Pharma Data

CDC: Vaccination Coverage Generally High by Age 24 Months. 23, 2020 — Vaccination coverage with many recommended vaccines is high by age 24 months, according to research published in the Oct. Coverage with at least two doses of influenza vaccine was higher for children born during 2016 to 2017 versus 2014 to 2015 (58.1

article thumbnail

Michelson Prizes- Next-Generation Grants: Advancing Immunology and Vaccine Innovation ePanel

keypoint

On March 24, 2023, Keystone Symposia will hosted a live ePanel event featuring the recipients of the Michelson Prizes: Next Generation Grants , an international prize that supports early-career researchers who are applying disruptive concepts and inventive processes to advance human immunology, vaccine discovery, and immunotherapy research.